# Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

> **NCT02785250** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 85 (estimated)

## Conditions studied

- Recurrent Epithelial Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Peritoneal Cancer

## Interventions

- **OTHER:** DPX-Survivac
- **DRUG:** Cyclophosphamide
- **DRUG:** Epacadostat (INCB024360)

## Key facts

- **NCT ID:** NCT02785250
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2020-10
- **Final completion:** 2025-05
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02785250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02785250, "Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02785250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*